Erenumab - Comprehensive Assessment of Efficacy in (High-Frequency) Episodic Migraine

Summary

The primary objective of this study is to evaluate the treatment benefit of erenumab on headache duration of at least moderate pain intensity.

Timeline

Start

2020-09-15

Primary completion

2023-10-26

Completion

2023-10-26

Outcome

Met primary endpoint

registry A negative change from baseline indicates a reduction in mean monthly hours of at least moderate headache pain intensity. NCT04252742 ↗

registry analysis (superiority test); Placebo vs Erenumab 140 mg SC Q4W; p < 0.001; LSM difference -7.95 (95% CI -11.45 to -4.46) NCT04252742 ↗

Publications

• Background Paiva da Silva Lima G, Rao R, Szabo G, Szklener S, Tassorelli C, Nastaj M, Chou DE, Khodavirdi AC, Chehrenama M, Zhu Y, Bhatia AK, Dodick DW. Comprehensive assessment of erenumab efficacy in participants with high-frequency episodic migraine with at least one previously failed preventive treatment: The EMBRACE study. Headache. 2026 Mar;66(3):658-671. doi: 10.1111/head.15071. Epub 2025 Oct 14.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Erenumab	Monoclonal antibody	140 mg	—

Indications